## **Thierry Passeron**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2776669/publications.pdf

Version: 2024-02-01

257 papers

8,851 citations

50566 48 h-index 82 g-index

292 all docs  $\begin{array}{c} 292 \\ \text{docs citations} \end{array}$ 

times ranked

292

10459 citing authors

#	Article	IF	Citations
1	Clinicopathologic and molecular analyses of cutaneous leiomyosarcoma: A retrospective, multicenter study of 79 cases. Journal of the American Academy of Dermatology, 2023, 88, 215-216.	0.6	4
2	Increased Activation of Innate Immunity and Pro-Apoptotic CXCR3B in Normal-Appearing Skin on the Lesional Site of Patients with Segmental Vitiligo. Journal of Investigative Dermatology, 2022, 142, 480-483.e2.	0.3	4
3	Outdoor sunscreen testing with highâ€intensity solar exposure in a Chinese and Caucasian population. Photodermatology Photoimmunology and Photomedicine, 2022, 38, 19-28.	0.7	5
4	Severe necrotizing myopathy after COVIDâ€19 vaccine with BNT162b2 and regimen with ipilimumab plus nivolumab in a patient with advanced melanoma. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	1.3	11
5	Efficacy of 308â€nm excimer therapy in alopecia areata: A retrospective study with longâ€term followâ€up. Photodermatology Photoimmunology and Photomedicine, 2022, 38, 507-510.	0.7	1
6	Efficacy and safety of methotrexate, omalizumab and dupilumab for bullous pemphigoid in patients resistant or contraindicated to oral steroids. A monocentric realâ€life study. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	1.3	15
7	A new <i>in vitro</i> method to predict <i>in vivo</i> photoprotection of skin hyperpigmentation induced by visible light. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 922-926.	1.3	4
8	Artificial Intelligence analysis of over half a million European and Chinese women reveals striking differences in the facial skin ageing process. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1136-1142.	1.3	19
9	Comparison of Two Rapid Assays for the Detection of BRAF V600 Mutations in Metastatic Melanoma including Positive Sentinel Lymph Nodes. Diagnostics, 2022, 12, 751.	1.3	3
10	The use of lasers in vitiligo, an overview. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 779-789.	1.3	8
11	Melasma: The need for tailored photoprotection to improve clinical outcomes. Photodermatology Photoimmunology and Photomedicine, 2022, 38, 515-521.	0.7	13
12	Self-applied topical interventions for melasma: a systematic review and meta-analysis of data from randomized, investigator-blinded clinical trials. British Journal of Dermatology, 2022, 187, 309-317.	1.4	8
13	CLEC12B Is a Melanocytic Gene Regulating the Color of the Skin. Journal of Investigative Dermatology, 2022, 142, 1858-1868.e8.	0.3	2
14	Targeting Discoidin Domain Receptors DDR1 and DDR2 overcomes matrixâ€mediated tumor cell adaptation and tolerance to BRAFâ€ŧargeted therapy in melanoma. EMBO Molecular Medicine, 2022, 14, e11814.	3.3	33
15	Scarring after chemical tattoo removal: a retrospective study. European Journal of Dermatology, 2022, 32, 131-132.	0.3	2
16	Secretion of IL1 by Dedifferentiated Melanoma Cells Inhibits JAK1-STAT3–Driven Actomyosin Contractility of Lymph Node Fibroblastic Reticular Cells. Cancer Research, 2022, 82, 1774-1788.	0.4	12
17	Prevention of Polymorphic Light Eruption Afforded by a Very High Broad-Spectrum Protection Sunscreen Containing Ectoin. Dermatology and Therapy, 2022, 12, 1603-1613.	1.4	1
18	Assessing the minimal important change in the vitiligo extent score and the self-assessment vitiligo extent score. Journal of the American Academy of Dermatology, 2021, 85, 1363-1364.	0.6	6

#	Article	IF	CITATIONS
19	Treatment of hidradenitis suppurativa using a long-pulsed hair removal neodymium:yttrium-aluminium-garnet laser: A multicenter, prospective, randomized, intraindividual, comparative trial. Journal of the American Academy of Dermatology, 2021, 84, 203-205.	0.6	12
20	Reactive angioendotheliomatosis revealing a glomerulopathy secondary to a monoclonal gammopathy successfully treated with lenalidomide. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e115-e118.	1.3	3
21	Negative SARS-CoV-2 PCR in patients with chilblain-like lesions. Lancet Infectious Diseases, The, 2021, 21, 315-316.	4.6	31
22	The continuous development of a complete and objective automatic grading system of facial signs from selfie pictures: Asian validation study and application to women of three ethnic origins, differently aged. Skin Research and Technology, 2021, 27, 183-190.	0.8	20
23	Clinical, Laboratory, and Interferon-Alpha Response Characteristics of Patients With Chilblain-like Lesions During the COVID-19 Pandemic. JAMA Dermatology, 2021, 157, 202.	2.0	92
24	Successful treatment of recalcitrant genital lichen planus with secukinumab. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e321-e323.	1.3	3
25	Low-Dose IL-2 for Treating Moderate to Severe Alopecia Areata: A 52-Week Multicenter Prospective Placebo-Controlled Study Assessing its Impact on T Regulatory Cell and NK Cell Populations. Journal of Investigative Dermatology, 2021, 141, 933-936.e6.	0.3	22
26	Discovery of a new molecule inducing melanoma cell death: dual AMPK/MELK targeting for novel melanoma therapies. Cell Death and Disease, 2021, 12, 64.	2.7	16
27	ITGBL1 is a new immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicity. Molecular Cancer, 2021, 20, 12.	7.9	12
28	Germline variants in exonic regions have limited impact on immune checkpoint blockade clinical outcomes in advanced melanoma. Pigment Cell and Melanoma Research, 2021, 34, 978-983.	1.5	4
29	Successful treatment of pyoderma gangrenosum associated with IgA gammopathy with the ILâ€1 receptor antagonist anakinra. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e447-e450.	1.3	1
30	Targeting Innate Immunity to Combat Cutaneous Stress: The Vitiligo Perspective. Frontiers in Immunology, 2021, 12, 613056.	2.2	19
31	Oral gliadinâ€protected superoxide dismutase in addition to phototherapy for treating nonâ€segmental vitiligo: A 24â€week prospective randomized placeboâ€controlled study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1725-1729.	1.3	14
32	Photoprotection according to skin phototype and dermatoses: practical recommendations from an expert panel. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1460-1469.	1.3	77
33	Development of a shared decisionâ€making tool in vitiligo: an international study. British Journal of Dermatology, 2021, 185, 787-796.	1.4	10
34	Editorial: Immunology of Vitiligo. Frontiers in Immunology, 2021, 12, 711080.	2.2	4
35	Daily photoprotection: What does it really mean?. Photodermatology Photoimmunology and Photomedicine, 2021, 37, 569-570.	0.7	1
36	Dual Covalent Inhibition of PKM and IMPDH Targets Metabolism in Cutaneous Metastatic Melanoma. Cancer Research, 2021, 81, 3806-3821.	0.4	9

3

#	Article	IF	CITATIONS
37	Adult skin acute stress responses to shortâ€term environmental and internal aggression from exposome factors. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1963-1975.	1.3	42
38	Photoprotection of the Skin from Visible Lightâ€'Induced Pigmentation: Current Testing Methods and Proposed Harmonization. Journal of Investigative Dermatology, 2021, 141, 2569-2576.	0.3	23
39	Relapse of chilblainâ€like lesions during the second wave of the COVIDâ€19 pandemic: a cohort followâ€up. British Journal of Dermatology, 2021, 185, 858-859.	1.4	8
40	CLEC12B Decreases Melanoma Proliferation by Repressing Signal Transducer and Activator of Transcription 3. Journal of Investigative Dermatology, 2021, , .	0.3	1
41	Efficacy and Safety of Tacrolimus 0.1% for the Treatment of Facial Vitiligo: A Multicenter Randomized, Double-Blinded, Vehicle-Controlled Study. Journal of Investigative Dermatology, 2021, 141, 1728-1734.	0.3	17
42	Male genital vitiligo. Annales De Dermatologie Et De Venereologie, 2021, , .	0.5	1
43	Analysis of Matched Skin and Gut Microbiome of Patients with Vitiligo Reveals Deep Skin Dysbiosis: Link with Mitochondrial and Immune Changes. Journal of Investigative Dermatology, 2021, 141, 2280-2290.	0.3	26
44	HeaLED: Assessment of skin healing under lightâ€emitting diode (LED) exposureâ€"A randomized controlled study versus placebo. Lasers in Surgery and Medicine, 2021, , .	1,1	1
45	Association of TRF2 expression and myeloid-derived suppressor cells infiltration with clinical outcome of patients with cutaneous melanoma. Oncolmmunology, 2021, 10, 1901446.	2.1	2
46	Vitiligo: 30Âyears to put together the puzzle pieces and to give rise to a new era of therapeutic options. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 2305-2307.	1.3	4
47	Laser treatment of epidermal nevi: A multicenter retrospective study with long-term follow-up. Journal of the American Academy of Dermatology, 2020, 83, 1606-1615.	0.6	13
48	Ingenol mebutate to treat lentigo maligna of the head (face and scalp): A prospective, multicenter, single-arm phase 2 trial indicates no benefit. Journal of the American Academy of Dermatology, 2020, 82, 731-733.	0.6	5
49	A systematic review of outcome reporting in laser treatments for dermatological diseases. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 47-53.	1,3	3
50	Association of combined <scp>PD</scp> ‣1 expression and tumourâ€infiltrating lymphocyte features with survival and treatment outcomes in patients with metastatic melanoma. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 984-994.	1.3	31
51	Short-term exposure to blue light emitted by electronic devices does not worsen melasma. Journal of the American Academy of Dermatology, 2020, 83, 913-914.	0.6	25
52	Efficacy and tolerability on melasma of a topical cosmetic product acting on melanocytes, fibroblasts and endothelial cells: a randomized comparative trial against 4% hydroquinone. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 897-903.	1.3	10
53	Everyday sunscreen use may compromise vitamin D in temperate climes: reply from authors. British Journal of Dermatology, 2020, 182, 1313-1314.	1.4	5
54	Photoprotection of the future: challenges and opportunities. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 447-454.	1.3	46

#	Article	IF	CITATIONS
55	Pulmonary Vascular Pathology in Covid-19. New England Journal of Medicine, 2020, 383, 886-889.	13.9	32
56	The skin exposome. An exciting growing field of research. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 3-3.	1.3	1
57	Clinical and biological impact of the exposome on the skin. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 4-25.	1.3	87
58	Apoptosis and pericyte loss in alveolar capillaries in COVID-19 infection: choice of markers matters. Author's reply. Intensive Care Medicine, 2020, 46, 1967-1968.	3.9	6
59	Pericyte alteration sheds light on micro-vasculopathy in COVID-19 infection. Intensive Care Medicine, 2020, 46, 1777-1778.	3.9	71
60	Comment on †Testing for BRAF fusions in patients with advanced BRAF/NRAS/KIT wild-type melanomas permits to identify patients who could benefit of anti-MEK targeted therapy'. Journal of Clinical Pathology, 2020, 73, 524-525.	1.0	0
61	Topical rapamycin versus betamethasone dipropionate ointment for treating oral erosive lichen planus: a randomized, doubleâ€blind, controlled study. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2384-2391.	1.3	8
62	Generic outcome set for the international registry on Laser trEAtments in Dermatology (LEAD): a protocol for a Delphi study to achieve consensus on <i>what</i> to measure. BMJ Open, 2020, 10, e038145.	0.8	3
63	First step in a new era for treatment of patients with vitiligo. Lancet, The, 2020, 396, 74-75.	6.3	8
64	Reliability and validity of the Vitiligo Signs of Activity Score (VSAS). British Journal of Dermatology, 2020, 183, 883-890.	1.4	24
65	Probiotics for recurrent idiopathic aphthous stomatitis in adults: a placeboâ€controlled randomized trial. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e239-e240.	1.3	4
66	Apremilast in Combination with Narrowband UVB in the Treatment of Vitiligo: A 52-Week Monocentric Prospective Randomized Placebo-Controlled Study. Journal of Investigative Dermatology, 2020, 140, 1533-1537.e2.	0.3	33
67	Skin manifestations associated with irritable bowel syndrome. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e651-e652.	1.3	2
68	Plasma cell-directed therapies in monoclonal gammopathy-associated scleromyxedema. Blood, 2020, 135, 1101-1110.	0.6	15
69	Functional Exhaustion of Type I and II Interferons Production in Severe COVID-19 Patients. Frontiers in Medicine, 2020, 7, 603961.	1.2	49
70	Epidermolysis bullosa simplex generalized severe induces a T helper 17 response and is improved by apremilast treatment. British Journal of Dermatology, 2019, 180, 357-364.	1.4	34
71	Combined/Sequential/Integrated Therapies for Vitiligo. , 2019, , 411-420.		0
72	Vitiligo/nonsegmental Vitiligo Including Acrofacial and Universalis. , 2019, , 41-51.		0

#	Article	IF	CITATIONS
73	New Methodology to Evaluate Sunscreens Under Outdoor Conditions: A Double-Blind, Randomized Intra-Individual Clinical Study of a Water-Based Broad-Spectrum SPF50+ Versus SPF15 (P3) and SPF50+. Dermatology and Therapy, 2019, 9, 589-599.	1.4	7
74	Filling the gap in the scoring of pigmentary disorders. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1201-1201.	1.3	0
75	æ³›å'é‡å°¦ EBS æ¨ä¸€ç§ç,Žç—‡æ€§ç—¾ç— British Journal of Dermatology, 2019, 180, e57-e57.	1.4	0
76	GAPDH Overexpression in the T Cell Lineage Promotes Angioimmunoblastic T Cell Lymphoma through an NF-κB-Dependent Mechanism. Cancer Cell, 2019, 36, 268-287.e10.	7.7	34
77	In-house Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-small Cell Lung Cancer and Melanoma Patients. Cancers, 2019, 11, 1271.	1.7	27
78	Acquired linear hyperpigmentation of the lips – a new entity?. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e230-e231.	1.3	1
79	Sunscreen photoprotection and vitamin D status. British Journal of Dermatology, 2019, 181, 916-931.	1.4	115
80	Innate lymphocyte-induced CXCR3B-mediated melanocyte apoptosis is a potential initiator of T-cell autoreactivity in vitiligo. Nature Communications, 2019, 10, 2178.	5.8	94
81	Caspase 1/11 Deficiency or Pharmacological Inhibition Mitigates Psoriasis-Like Phenotype inÂMice. Journal of Investigative Dermatology, 2019, 139, 1306-1317.	0.3	16
82	A case of lymphoplasmacytic plaque in children. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e171-e172.	1.3	1
83	Laser treatment of hyperpigmented lesions: position statement of the European Society of Laser in Dermatology. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 987-1005.	1.3	48
84	EBS generalized severe is an inflammatory disease. British Journal of Dermatology, 2019, 180, e44-e44.	1.4	0
85	å‰ä¿æŠå'Œç»´ç"Ÿç´ D 状怕 British Journal of Dermatology, 2019, 181, e138.	1.4	0
86	Photoprotection and vitamin D status. British Journal of Dermatology, 2019, 181, e126.	1.4	0
87	Successful treatment of resistant condylomas with nitrizinc complex solution: a retrospective study in 11 patients. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e88-e89.	1.3	3
88	Comparison of microneedling and full surface erbium laser dermabrasion for autologous cell suspension grafting in nonsegmental vitiligo: a randomized controlled trial. British Journal of Dermatology, 2019, 180, 1539-1540.	1.4	13
89	The key question of irradiance when it comes to the effects of visible light in the skin. Journal of Dermatological Science, 2019, 93, 69-70.	1.0	14
90	Ingenol mebutate to treat lentigo maligna of the head (face and scalp): A prospective and multicenter single-arm phase 2 trial Journal of Clinical Oncology, 2019, 37, e21051-e21051.	0.8	1

#	Article	IF	Citations
91	Abstract 4889: Comparison of tumor mutational burden using the Ion Oncomineâ, TML and FoundationOneâ, assays with routine clinical FFPE tissue samples to predict durable clinical benefit in lung cancer and melanoma patients - a multivariate analysis integrating PD-L1 and CD8+evaluation., 2019		0
92	Atorvastatin in Combination With Narrowband UV-B in Adult Patients With Active Vitiligo. JAMA Dermatology, 2018, 154, 725.	2.0	20
93	Laser hair removal after surgery vs. surgery alone for the treatment of pilonidal cysts: a retrospective case–control study. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 2031-2033.	1.3	9
94	Psoriatic arthritis screening by the dermatologist: development and first validation of the â€~ <scp>PURE</scp> â€4 scale'. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1950-1953.	, 1.3	26
95	Development and validation of a reproducible model for studying postâ€inflammatory hyperpigmentation. Pigment Cell and Melanoma Research, 2018, 31, 649-652.	1.5	25
96	Melasma, a photoaging disorder. Pigment Cell and Melanoma Research, 2018, 31, 461-465.	1.5	136
97	Successful treatment of severe psoriasis relapse with secukinumab (interleukin 17 A inhibitor) after abrupt brodalumab (interleukin 17 receptor inhibitor) discontinuation: A retrospective study evaluating long-term efficacy and safety. Journal of the American Academy of Dermatology, 2018, 79, 758-760.	0.6	6
98	Low-Protein Diet Induces IRE1α-Dependent Anticancer Immunosurveillance. Cell Metabolism, 2018, 27, 828-842.e7.	7.2	99
99	Melanocytes Sense Blue Light and Regulate Pigmentation through Opsin-3. Journal of Investigative Dermatology, 2018, 138, 171-178.	0.3	225
100	Comparison of two picosecond lasers to a nanosecond laser for treating tattoos: a prospective randomized study on 49 patients. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 265-270.	1.3	36
101	Painful acute thyroiditis following a first cure of Ipilimumab plus Nivolumab for metastatic melanoma. Melanoma Research, 2018, 28, 368-369.	0.6	3
102	Antiphospholipid Syndrome Following Pembrolizumab Treatment of Stage IIIB Unresectable Melanoma. JAMA Dermatology, 2018, 154, 1354.	2.0	11
103	Treatment of Severe Hailey-Hailey Disease With Apremilast. JAMA Dermatology, 2018, 154, 1453.	2.0	28
104	Efficacy and safety data for checkpoint inhibitors in advanced melanoma under real-life conditions: A monocentric study conducted in Nice from 2010 to 2016. Annales De Dermatologie Et De Venereologie, 2018, 145, 649-658.	0.5	3
105	E2F1 inhibition mediates cell death of metastatic melanoma. Cell Death and Disease, 2018, 9, 527.	2.7	32
106	Pulmonary sarcoid-like granulomatosis induced by nivolumab. British Journal of Dermatology, 2017, 176, 1060-1063.	1.4	106
107	Metformin monotherapy in melanoma: a pilot, open″abel, prospective, and multicentric study indicates no benefit. Pigment Cell and Melanoma Research, 2017, 30, 378-380.	1.5	23
108	Sensitivity and specificity of BP180 NC16A enzyme-linked immunosorbent assay for the diagnosis of pemphigoid gestationis. Journal of the American Academy of Dermatology, 2017, 76, 560-562.	0.6	27

#	Article	IF	CITATIONS
109	Association of Oncogenic Mutations in Patients With Advanced Cutaneous Squamous Cell Carcinomas Treated With Cetuximab. JAMA Dermatology, 2017, 153, 291.	2.0	29
110	Prepubertal vulvar fibroma, a rare entity little known to dermatologists: report of two cases. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e448-e449.	1.3	2
111	Centrifugal hypomelanosis: a new clinical phenotype of Malassezia infection. European Journal of Dermatology, 2017, 27, 72-73.	0.3	0
112	Efficacy and Tolerance of Anti–Tumor Necrosis Factor α Agents in Cutaneous Sarcoidosis. JAMA Dermatology, 2017, 153, 681.	2.0	46
113	A method to assess the protective efficacy of sunscreens against visible lightâ€induced pigmentation. Photodermatology Photoimmunology and Photomedicine, 2017, 33, 260-266.	0.7	44
114	Topical corticosteroids application in the evening is more effective than in the morning in psoriasis: in reply. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e406-e407.	1.3	2
115	Medical and Maintenance Treatments for Vitiligo. Dermatologic Clinics, 2017, 35, 163-170.	1.0	39
116	Posterior reversible encephalopathy syndrome due to combination of vemurafenib and cobimetinib for metastatic melanoma. Pigment Cell and Melanoma Research, 2017, 30, 262-264.	1.5	7
117	Interleukin 6 and high-sensitivity C-reactive protein are potential predictive markers of response to infliximab in hidradenitis suppurativa. Journal of the American Academy of Dermatology, 2017, 76, 156-158.	0.6	27
118	621 Melanocytes sense blue-light and regulate the pigmentation through theÂOpsinÂ3. Journal of Investigative Dermatology, 2017, 137, S299.	0.3	4
119	Treatment of Elastosis Perforans Serpiginosa Using a Fractional Carbon Dioxide Laser. JAMA Dermatology, 2017, 153, 1063.	2.0	5
120	Clinical Outcomes of Metastatic Melanoma Treated With Checkpoint Inhibitors and Multisite Radiotherapy. JAMA Dermatology, 2017, 153, 1056.	2.0	13
121	Repigmentation in vitiligo: position paper of the Vitiligo Global Issues Consensus Conference. Pigment Cell and Melanoma Research, 2017, 30, 28-40.	1.5	38
122	Topical corticosteroids application in the evening is more effective than in the morning in psoriasis: results of a prospective comparative study. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e263-e264.	1.3	6
123	Exacerbation of Hailey–Hailey disease by topiramate. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e185-e186.	1.3	1
124	Successful treatment of angiokeratoma circumscriptum naeviforme with long pulse alexandrite laser. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e186-e187.	1.3	2
125	The skin aging exposome. Journal of Dermatological Science, 2017, 85, 152-161.	1.0	466
126	Differential expression of <scp>CXCL</scp> 9, <scp>CXCL</scp> 10, and <scp>IFN</scp> â€∢i>γ in vitiligo and <i>alopecia areata</i> patients. Pigment Cell and Melanoma Research, 2017, 30, 259-261.	1.5	22

#	Article	IF	CITATIONS
127	Micro holes for delivering melanocytes into the skin: an exÂvivo approach. Pigment Cell and Melanoma Research, 2016, 29, 481-483.	1.5	10
128	Evaluation of learning disabilities in segmental neurofibromatosis. British Journal of Dermatology, 2016, 174, 1404-1406.	1.4	4
129	Ivermectin cream improves health-related quality of life in patients with rosacea: data from a randomized trial. British Journal of Dermatology, 2016, 175, 1366-1368.	1.4	6
130	Rebound pustular psoriasis after brodalumab discontinuation. British Journal of Dermatology, 2016, 175, 1065-1066.	1.4	15
131	Long pulse Alexandrite laser for recalcitrant viral warts on the hands. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1394-1395.	1.3	4
132	Maintenance of remission following successful treatment of papulopustular rosacea with ivermectin 1% cream vs. metronidazole 0.75% cream: 36â€week extension of the ⟨scp⟩ATTRACT⟨/scp⟩ randomized study. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 829-836.	1.3	46
133	Compounds Triggering ER Stress Exert Anti-Melanoma Effects and Overcome BRAF Inhibitor Resistance. Cancer Cell, 2016, 29, 805-819.	7.7	201
134	The Mechanism of Pigmentation. , 2016, , 1-23.		3
135	Topical timolol for chronic wounds in patients with junctional epidermolysis bullosa. Journal of the American Academy of Dermatology, 2016, 75, e223-e224.	0.6	17
136	Appearance of lentigines in psoriasis patients treated with apremilast. Journal of the American Academy of Dermatology, 2016, 75, 1251-1252.	0.6	10
137	Fractionated bipolar radiofrequency and bipolar radiofrequency potentiated by infrared light for treating striae: A prospective randomized, comparative trial with objective evaluation. Lasers in Surgery and Medicine, 2016, 48, 245-253.	1.1	25
138	Treatment of resistant portâ€wine stains with bosentan and pulsed dye laser: a pilot prospective study. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1432-1434.	1.3	5
139	Pigmented macules of bony prominences (PMBP): A distinct presentation in patients with red hair. Journal of the American Academy of Dermatology, 2016, 74, 383-385.	0.6	1
140	Prognosis and response to laser treatment of early-onset hypertrophic port-wine stains (PWS). Journal of the American Academy of Dermatology, 2016, 75, 64-68.	0.6	21
141	NF-kB2 induces senescence bypass in melanoma via a direct transcriptional activation of EZH2. Oncogene, 2016, 35, 2735-2745.	2.6	49
142	Interest of highâ€definition optical coherent tomography (HDâ€OCT) for nonâ€invasive imaging of dermatofibroma: a pilot study. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 485-487.	1.3	3
143	Copper Bromide Laser vs Triple-Combination Cream for the Treatment of Melasma. JAMA Dermatology, 2015, 151, 791.	2.0	22
144	Comparative Methods for Improving Transepidermal Methylaminolevulinate Delivery. JAMA Dermatology, 2015, 151, 1371.	2.0	7

#	Article	IF	CITATIONS
145	Ultrasound study of entheses in psoriasis patients with or without musculoskeletal symptoms: A prospective study. Joint Bone Spine, 2015, 82, 267-271.	0.8	36
146	Indications and Limitations of Afamelanotide for Treating Vitiligo. JAMA Dermatology, 2015, 151, 349.	2.0	14
147	New onset of articular inflammatory manifestations in patients with hidradenitis suppurativa under treatment with infliximab. Joint Bone Spine, 2015, 82, 362-364.	0.8	9
148	Acquired dermal melanocytosis of the nose. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 827-829.	1.3	5
149	Successful treatment with 532â€nm Qâ€switched Nd: <scp>YAG</scp> laser of cutaneous siderosis following intravenous iron extravasation. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 818-819.	1.3	8
150	Transcriptional Analysis of Vitiligo Skin Reveals the Alteration of WNT Pathway: A Promising Target for Repigmenting Vitiligo Patients. Journal of Investigative Dermatology, 2015, 135, 3105-3114.	0.3	140
151	Endothelial Cells Promote Pigmentation through Endothelin Receptor B Activation. Journal of Investigative Dermatology, 2015, 135, 3096-3104.	0.3	87
152	Treatment of keloids with laser-assisted topical steroid delivery: a retrospective study of 23 cases. Dermatologic Therapy, 2015, 28, 74-78.	0.8	76
153	Maintenance Therapy of Adult Vitiligo with 0.1% Tacrolimus Ointment: A Randomized, Double Blind, Placebo–Controlled Study. Journal of Investigative Dermatology, 2015, 135, 970-974.	0.3	122
154	Prevention of melasma relapses with sunscreen combining protection against UV and short wavelengths of visible light: A prospective randomized comparative trial. Journal of the American Academy of Dermatology, 2015, 72, 189-190.e1.	0.6	122
155	Hypochromic vitiligo: delineation of a new entity. British Journal of Dermatology, 2015, 172, 716-721.	1.4	25
156	Successful Treatment of Refractory Neuropathic Pruritus with Capsaicin 8% Patch: A Bicentric Retrospective Study with Long-term Follow-up. Acta Dermato-Venereologica, 2014, 95, 864-5.	0.6	13
157	Reflectance Confocal Microscopy Features of Degos Disease. JAMA Dermatology, 2014, 150, 96.	2.0	4
158	latrogenic kwashiorkor developing after bypass surgery. Clinical and Experimental Dermatology, 2014, 39, 113-114.	0.6	3
159	Interest of confocal laser scanning microscopy for the diagnosis and treatment monitoring of demodicosis. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 255-257.	1.3	13
160	Impact of systemic treatment of psoriasis on inflammatory parameters and markers of comorbidities and cardiovascular risk: results of a prospective longitudinal observational study. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 1186-1191.	1.3	24
161	Treatment of Linear and Whorled Hypermelanosis With Q-Switched Laser. Dermatologic Surgery, 2014, 40, 1044-1046.	0.4	4
162	Risk for Nevus Transformation and Melanoma Proliferation and Invasion During Natalizumab Treatment. JAMA Dermatology, 2014, 150, 901.	2.0	13

#	Article	IF	CITATIONS
163	Effects of Low-Dose Recombinant Interleukin 2 to Promote T-Regulatory Cells in Alopecia Areata. JAMA Dermatology, 2014, 150, 748.	2.0	185
164	FisiologÃa del sistema pigmentario. Melanogénesis. EMC - DermatologÃa, 2014, 48, 1-11.	0.1	2
165	Macular eruption revealing hypomelanotic cutaneous melanoma metastases: Diagnostic role of dermoscopy. Journal of the American Academy of Dermatology, 2014, 70, e7-e9.	0.6	2
166	Diagnosis and treatment monitoring of toenail onychomycosis by reflectance confocal microscopy: Prospective cohort study in 58 patients. Journal of the American Academy of Dermatology, 2014, 71, 56-61.	0.6	34
167	Inhibition of Melanogenesis by the Antidiabetic Metformin. Journal of Investigative Dermatology, 2014, 134, 2589-2597.	0.3	53
168	Laserâ€assisted depigmentation for resistant vitiligo: a retrospective case series with longâ€term followâ€up. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 374-377.	1.3	8
169	Treatment of inflammatory linear verrucous epidermal nevus with 2940Ânm erbium fractional laser. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 824-825.	1.3	7
170	Solar urticaria to visible light triggered by light-emitting diode therapy. Journal of the American Academy of Dermatology, 2014, 71, e74-e75.	0.6	2
171	Trichoblastoma with dermoscopic features of a malignant tumor: Three cases. Journal of the American Academy of Dermatology, 2014, 71, e63-e64.	0.6	6
172	Differences in visible lightâ€induced pigmentation according to wavelengths: a clinical and histological study in comparison with ⟨scp⟩ UVB⟨/scp⟩ exposure. Pigment Cell and Melanoma Research, 2014, 27, 822-826.	1.5	149
173	Treatment of port wine stains with pulsed dye laser and topical timolol: a multicenter randomized controlled trial. British Journal of Dermatology, 2014, 170, 1350-1353.	1.4	29
174	PGJ2 restores RA sensitivity in melanoma cells by decreasing PRAME and EZH2. Journal of Dermatological Science, 2014, 73, 258-261.	1.0	5
175	Treatment of granuloma annulare with the 595â€nm pulsed dye laser, a multicentre retrospective study with longâ€term followâ€up. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 785-788.	1.3	9
176	Use of high-definition optical coherent tomography (HD-OCT) for imaging of melanoma. British Journal of Dermatology, 2013, 169, 950-952.	1.4	16
177	Superficial Lymphangioma Treated with Fractional Ablative Laser: A Case Report with Clinical and Reflectance Confocal Microscopy Evaluation. Dermatologic Surgery, 2013, 39, 141-143.	0.4	11
178	Long-lasting effect of vascular targeted therapy of melasma. Journal of the American Academy of Dermatology, 2013, 69, e141-e142.	0.6	35
179	Guidelines for the management of vitiligo: the European Dermatology Forum consensus. British Journal of Dermatology, 2013, 168, 5-19.	1.4	328
180	Melasma pathogenesis and influencing factors $\hat{a}\in$ an overview of the latest research. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 5-6.	1.3	93

#	Article	IF	CITATIONS
181	Usefulness of Immunocytochemistry for the Detection of the BRAFV600E Mutation in Circulating Tumor Cells from Metastatic Melanoma Patients. Journal of Investigative Dermatology, 2013, 133, 1378-1381.	0.3	39
182	Secondary Hyperpigmentation During Interferon Alfa Treatment for Chronic Hepatitis C Virus Infection. JAMA Dermatology, 2013, 149, 675.	2.0	17
183	Flexural Agminated Eruptive Nevi in Langerhans Cell Histiocytosis. JAMA Dermatology, 2013, 149, 635.	2.0	10
184	Kaposi's varicelliform eruption in a patient with pityriasis rubra pilaris (pityriasis rubra pilaris) Tj ETQq0 0 0 rgBT /	Overlock 1 1.3	10 Tf 50 622
185	Localized depigmentation on genital melanosis: a clue for the understanding of vitiligo. British Journal of Dermatology, 2013, 168, 663-664.	1.4	9
186	Major Clinical Response to a BRAF Inhibitor in a Patient With a <i>BRAF</i> L597R–Mutated Melanoma. Journal of Clinical Oncology, 2013, 31, e324-e326.	0.8	53
187	Dermoscopic changes of melanocytic nevi after laser hair removal. European Journal of Dermatology, 2013, 23, 121-123.	0.3	10
188	Use of 2940-nm Erbium-Yag Fractional Laser for treating the skin texture changes in stabilized Parry Romberg Syndrome. European Journal of Dermatology, 2013, 23, 908-909.	0.3	5
189	Vitiligo und andere Hypopigmentierungen. , 2013, , 143-150.		0
190	Activation of the Unfolded Protein Response in Vitiligo: The Missing Link?. Journal of Investigative Dermatology, 2012, 132, 2502-2504.	0.3	40
191	Labial Melanotic Macule: A Potential Pitfall on Reflectance Confocal Microscopy. Dermatology, 2012, 224, 209-211.	0.9	14
192	Disturbi pigmentari. EMC - AKOS - Trattato Di Medicina, 2012, 14, 1-10.	0.0	0
193	Lasers. Annales De Dermatologie Et De Venereologie, 2012, 139, S159-S165.	0.5	4
194	Effect of a preceding laser dermabrasion on the outcome of combined therapy with narrowband ultraviolet B and potent topical steroids for treating nonsegmental vitiligo in resistant localizations. British Journal of Dermatology, 2012, 166, 208-211.	1.4	69
195	The deceptive nature of UVA tanning versus the modest protective effects of UVB tanning on human skin. Pigment Cell and Melanoma Research, 2011, 24, 136-147.	1.5	103
196	Reflectance Confocal Microscopy for Recurrent Lentigo Maligna. Dermatologic Surgery, 2011, 37, 1519-1524.	0.4	15
197	Signalling and chemosensitivity assays in melanoma: is mutated status a prerequisite for targeted therapy?. Experimental Dermatology, 2011, 20, 1030-1032.	1.4	20
198	Melasma Treatment With Pulsed-Dye Laser and Triple Combination Cream: A Prospective, Randomized, Single-Blind, Split-Face Study. Archives of Dermatology, 2011, 147, 1106.	1.7	93

#	Article	IF	Citations
199	Pigmentary Sequelae of AIDS-Related Cutaneous Kaposi Sarcoma. Archives of Dermatology, 2011, 147, 779.	1.7	7
200	Nd:YAG Laser Treatment for Multiple Cutaneous Glomangiomas: Report of 3 Cases. Archives of Dermatology, 2011, 147, 255.	1.7	11
201	AMP kinase-related kinase NUAK2 affects tumor growth, migration, and clinical outcome of human melanoma. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 6597-6602.	3.3	46
202	Pigmentation and Hypopigmentation: Vitiligo and Other Disorders. , 2011, , 157-164.		0
203	<i>In vivo</i> reflectance confocal microscopy detects pigmentary changes in melasma at a cellular level resolution. Experimental Dermatology, 2010, 19, e228-33.	1.4	105
204	Erythema gyratum repens, not always a bad omen for patients. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 738-739.	1.3	15
205	Evolution of Nevi During Treatment With Natalizumab. Archives of Dermatology, 2010, 147, 72.	1.7	21
206	308-nm excimer lamp vs. 308-nm excimer laser for treating vitiligo: a randomized study. British Journal of Dermatology, 2010, 163, 188-192.	1.4	71
207	Glycoprotein nonmetastatic melanoma protein b, a melanocytic cell marker, is a melanosomeâ€specific and proteolytically released protein. FASEB Journal, 2010, 24, 1616-1629.	0.2	91
208	Urticarial Vasculitis Secondary to H1N1 Vaccination. Acta Dermato-Venereologica, 2010, 90, 651-652.	0.6	11
209	Drug Rash with Eosinophilia and Systemic Symptoms due to Telaprevir. Dermatology, 2010, 221, 303-305.	0.9	46
210	Tumeur ténosynoviale bénigne à cellules géantes. Annales De Dermatologie Et De Venereologie, 2010, 137, 171-172.	0.5	1
211	A noninvasive technique, reflectance confocal microscopy, for the characterization of melanocyte loss in untreated and treated vitiligo lesions. Journal of the American Academy of Dermatology, 2010, 63, e97-e100.	0.6	18
212	Evidence-Based Medicine Perspective. , 2010, , 461-469.		0
213	Combined Therapies for Vitiligo. , 2010, , 417-421.		0
214	Microarray analysis sheds light on the dedifferentiating role of agouti signal protein in murine melanocytes via the Mc1r. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 1802-1807.	3.3	73
215	Blue Pseudochromhidrosis Secondary to Topiramate Treatment. Acta Dermato-Venereologica, 2009, 89, 538-539.	0.6	15
216	Pulsed dye laser-mediated photodynamic therapy for acne inversa is not successful: A pilot study on four cases. Journal of Dermatological Treatment, 2009, 20, 297-298.	1.1	22

#	Article	IF	Citations
217	Forskolin Protects Keratinocytes from UVB-Induced Apoptosis and Increases DNA Repair Independent of its Effects on Melanogenesis. Journal of Investigative Dermatology, 2009, 129, 162-166.	0.3	48
218	What are melanocytes <i>really</i> li>doing all day long…?. Experimental Dermatology, 2009, 18, 799-819.	1.4	239
219	Comparative Treatment of Extragenital Lichen Sclerosus with Methylaminolevulinic Acid Pulsed Dye Laser-Mediated Photodynamic Therapy or Pulsed Dye Laser Alone. Dermatologic Surgery, 2009, 35, 878-880.	0.4	9
220	Upregulation of SOX9 inhibits the growth of human and mouse melanomas and restores their sensitivity to retinoic acid. Journal of Clinical Investigation, 2009, 119, 954-63.	3.9	88
221	Dickkopf 1 (DKK1) regulates skin pigmentation and thickness by affecting Wnt/ βâ€catenin signaling in keratinocytes. FASEB Journal, 2008, 22, 1009-1020.	0.2	126
222	Treatment of Oral Erosive Lichen Planus With 1% Pimecrolimus Cream. Archives of Dermatology, 2007, 143, 472-6.	1.7	62
223	SOX9 is a key player in ultraviolet B-induced melanocyte differentiation and pigmentation. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 13984-13989.	3.3	116
224	Sialylated Core 1 O-Glycans Influence the Sorting of Pmel17/gp100 and Determine Its Capacity to Form Fibrils. Journal of Biological Chemistry, 2007, 282, 11266-11280.	1.6	42
225	Effect of Tacrolimus on Vitiligo in Absence of UV Radiation Exposure. Archives of Dermatology, 2007, 143, 115.	1.7	5
226	The Effects of Dickkopf 1 on Gene Expression and Wnt Signaling by Melanocytes: Mechanisms Underlying Its Suppression of Melanocyte Function and Proliferation. Journal of Investigative Dermatology, 2007, 127, 1217-1225.	0.3	89
227	Regulation of human skin pigmentation and responses to ultraviolet radiation. Pigment Cell & Melanoma Research, 2007, 20, 2-13.	4.0	188
228	Immunohistochemistry and in situ hybridization in the study of human skin melanocytes. Experimental Dermatology, 2007, 16, 162-170.	1.4	20
229	Practical methods for detecting melanocytes in the skin and their responses to UV. FASEB Journal, 2007, 21, A774.	0.2	0
230	Use of the 308-nm excimer laser for psoriasis and vitiligo. Clinics in Dermatology, 2006, 24, 33-42.	0.8	69
231	Lack of Efficacy of Tacrolimus in the Treatment of Vitiligo in the Absence of UV-B Exposure. Archives of Dermatology, 2006, 142, 252.	1.7	36
232	Prebiotics and synbiotics: two promising approaches for the treatment of atopic dermatitis in children above 2 years. Allergy: European Journal of Allergy and Clinical Immunology, 2006, 61, 431-437.	2.7	132
233	What's new in hypochromy. Journal of Dermatological Treatment, 2006, 17, 70-73.	1.1	2
234	Neurogenic Pulmonary Oedema Mimicking an Anaphylactic Reaction to interferon $\hat{l}_{\pm}$ -2b. Clinical Oncology, 2005, 17, 665.	0.6	1

#	Article	IF	CITATIONS
235	Melanin Pigmentary Disorders: Treatment Update. Dermatologic Clinics, 2005, 23, 209-226.	1.0	90
236	Physiopathology and genetics of vitiligo. Journal of Autoimmunity, 2005, 25, 63-68.	3.0	264
237	Genetic disorders of pigmentation. Clinics in Dermatology, 2005, 23, 56-67.	0.8	51
238	Topical Tacrolimus and the 308-nm Excimer Laser. Archives of Dermatology, 2004, 140, 1065-9.	1.7	164
239	Cyclic AMP promotes a peripheral distribution of melanosomes and stimulates melanophilin/Slac2â€a and actin association. FASEB Journal, 2004, 18, 989-991.	0.2	47
240	Efficacy of the 308-nm Excimer Laser in the Treatment of Mycosis Fungoides. Archives of Dermatology, 2004, 140, 1291-3.	1.7	30
241	Chronic anal ulceration due to nicorandil. British Journal of Dermatology, 2004, 150, 394-396.	1.4	32
242	Infectious and toxic cellulitis due to suicide attempt by subcutaneous injection of ricin. British Journal of Dermatology, 2004, 150, 154-154.	1.4	18
243	Invasive Fungal Dermatitis in a 770 Gram Neonate. Pediatric Dermatology, 2004, 21, 260-261.	0.5	19
244	Treatment of erosive oral lichen planus by the 308 nm excimer laser. Lasers in Surgery and Medicine, 2004, 34, 205-205.	1.1	28
245	Treatment of vitiligo by 308-nm excimer laser: An evaluation of variables affecting treatment response. Lasers in Surgery and Medicine, 2004, 35, 152-156.	1.1	84
246	Traitement du vitiligo de l'enfant par le laser excimer à 308 nm. Annales De Dermatologie Et De Venereologie, 2004, 131, 619.	0.5	1
247	308-nm excimer laser therapy in alopecia areata. Journal of the American Academy of Dermatology, 2004, 51, 837-838.	0.6	74
248	Extensive cutaneous herpes following meningococcal meningitis: two cases. British Journal of Dermatology, 2003, 149, 1077-1078.	1.4	11
249	The new 940-nanometer diode laser: An effective treatment for leg venulectasia. Journal of the American Academy of Dermatology, 2003, 48, 768-774.	0.6	54
250	Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) Due to Streptomycin. Acta Dermato-Venereologica, 2003, 84, 92-94.	0.6	13
251	Kawasaki disease with exceptional cutaneous manifestations. European Journal of Pediatrics, 2002, 161, 228-230.	1.3	7
252	Treatment of vitiligo by topical calcipotriol. Journal of the European Academy of Dermatology and Venereology, 2002, 16, 137-138.	1.3	65

#	Article	IF	CITATIONS
253	Thalidomide-induced amenorrhoea: two cases. British Journal of Dermatology, 2001, 144, 1292-1293.	1.4	57
254	Paraneoplastic pemphigus presenting as erosive lichen planus. British Journal of Dermatology, 1999, 140, 552-553.	1.4	18
255	UVB Therapy for Pigmentary Disorders. , 0, , 1183-1187.		2
256	Recurrence of metastatic Merkel carcinoma after cessation of avelumab in a patient previously with a complete response. , $0$ , , .		0
257	Laser for Repigmenting Vitiligo. , 0, , 255-258.		0